Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer

Annals of Surgical Oncology

Volumn 11, Issue 10, 2004, Pages 907-914

  Becker, Stephen ^a   Cazares, Lisa H ^a,b   Watson, Patrice ^c   Lynch, Henry ^c   Semmes, O John ^a,b   Drake, Richard R ^a,b   Laronga, Christine ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Virginia Prostate Center   (United States)

^c CREIGHTON UNIVERSITY   (United States)

Author keywords

BRCA 1; Breast cancer; Protein profiling; Serum

Indexed keywords

BRCA1 PROTEIN; TUMOR MARKER;

ACCURACY; ADULT; AGED; ALGORITHM; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; COHORT ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENE MUTATION; HETEROZYGOTE; HUMAN; OCCULT CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SERUM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; DIFFERENTIAL DIAGNOSIS; GENETIC PREDISPOSITION; GENETICS; MASS SPECTROMETRY; METHODOLOGY; MIDDLE AGED; NUCLEOTIDE SEQUENCE; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BRCA1 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 16544370448     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.03.557     Document Type: Article

References (14)

1. Reynolds T. Study clarifies risk of breast, ovarian cancer among mutation carriers. JNCI 2003;95:1816-18.
2. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9.
3. Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61:6029-33.
4. Wright Jr GL, Cazares LH, Leung SM, et al. ProteinChip surface enhanced laser desorption/ionization mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer and Prostate Diseases 1999;2:264-76.
5. Cazares LH, Adam, B-L, Ward MD, et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by SELDI mass spectrometry. Clin Cancer Res 2002;8:2541-52.
6. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
7. Petricoin EF, Ardekani A, Hitt B, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
8. Li J, Zhang Z, Rosenzweig J, Wang Y, Chan D. Proteomics and bioinfomiatics approaches for identification of serum biomarkers to detect breast cancer. Clinical Chemistry 2002;48:1296-303.
9. Vlahou A, Laronga C, Wilson L, et al. A novel approach towards development of a rapid blood test for breast cancer. Clin Breast Cancer 2003;4:203-9.
10. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: Differences in breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic breast cases. Lancet 1997;349:1505-10.
11. King MC, Marks JH, Mandell JB, and the New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
12. Wright Jr GL. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002;2:549-63.
13. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA-1 or BRCA-2 mutation. N Engl J Med 2001;345:159-64.
14. van Oostrom I, Meijers-Heijboer H, Ladder LN, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow- up study. J Clin Oncol 2003;21:3867-74.